FDAnews Drug Daily Bulletin

Generics Lose as Court Protects Pfizer’s Lyrica Through 2018

Aug. 7, 2012
A A
Pfizer is trumpeting its exclusive rights to one of its best-selling products until late 2018 after a Delaware district court upheld its patents on pain and seizure drug Lyrica. A Wilmington, Del., federal judge ruled Teva Pharmaceuticals and other generic-drug applicants would infringe on Lyrica’s (pregabalin) patents and enjoined them from making or selling their products until then.
Generic Line